Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (4541)	6/23/1998 1:43:00 AM
From: Bhag Karamchandani	Read Replies (1) \| Respond to of 6136

"I think they have an intelligently designed trial plan, and they believe they have selected the right dose range ..and their goal would be to get a 50% increase in survival time with terminal patients" Has AGPH put their P3 plan for AG3340 ( sorry for transposing the numbers in my last post) in the public domain?. If their PII/III dosages correspond to PI, the only factor which can be altered is the duration of the combined treatment regimen and end pints. If the aim is to establish a 3 month life extension in terminal patients (6 month prospect) the drug may show statistically significant positive results (vitally important as that is for those affected) and still not rate as more than a marginal commercial success. Perhaps someone can either validate or comment on the conclusion. It does appear that AG3340 has better tolerance profile than the British Biotech MMP inhibitor? If true, this is encouraging but is it enough? If AG3340 is the best choice they have in their repertoire what does it say about the state of their science at the point it was deemed to be the best bet?? This statement is not without acknowledging that Cancer treatments, at least in the near term, are likely to be combination therapies aimed at controlling the disease and reducing it to a chronic but treatable condition - at least for some forms of cancer. AG3340 does not seem to have the 'killer' efficacy characteristics of Viracept.